| Entry |
|
|---|
| Name |
Clobazam (JAN/USAN/INN);
Mystan (TN);
Onfi (TN)
|
|---|
| Product |
|
|---|
| Formula |
C16H13ClN2O2
|
|---|
| Exact mass |
300.0666
|
|---|
| Mol weight |
300.7396
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Neuropsychiatric agent
DG01567 GABA-A receptor agonist
DG01914 Anxiolytics, benzodiazepine derivatives
DG02036 Antiepileptics, benzodiazepine derivatives
Cyp substrate
DG01639 CYP2C19 substrate
DG01633 CYP3A substrate
Cyp inhibitor
DG01645 CYP2D6 inhibitor
|
|---|
| Remark |
| Therapeutic category: | 1139 |
|
|---|
| Efficacy |
Anticonvulsant, Minor tranquilizer |
|---|
| Disease |
Lennox-Gastaut syndrome [DS: H01813] |
|---|
| Comment |
Benzodiazepine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP2C19 [HSA: 1557]
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05B ANXIOLYTICS
N05BA Benzodiazepine derivatives
N05BA09 Clobazam
D01253 Clobazam (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Anticonvulsants
Gamma-aminobutyric Acid (GABA) Augmenting Agents
Clobazam
D01253 Clobazam (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
113 Antiepileptics
1139 Others
D01253 Clobazam (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Ion channels
Ligand-gated ion channels
GABA (ionotropic)
GABR
D01253 Clobazam (JAN/USAN/INN) <JP/US>
Drug classes of therapeutic agents [br08360.html]
Neurological agents
D01253
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D01253
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01253
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01253
Pharmacogenomic biomarkers in FDA drug labels [br08341.html]
Polymorphisms and germline mutations
D01253
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 21
1 C5x C 20.8440 -16.6025
2 C1x C 21.7290 -15.5177
3 C5x C 21.4335 -14.1745
4 N1y N 20.1974 -13.5636
5 N1y N 19.4423 -16.6153
6 C8y C 18.9128 -14.1417
7 C8y C 18.5788 -15.4592
8 C8x C 17.2356 -15.7546
9 C8y C 16.2236 -14.8026
10 C8x C 16.5605 -13.4152
11 C8x C 17.9036 -13.1197
12 X Cl 14.8804 -15.0980
13 O5x O 21.3522 -17.8843
14 C8y C 18.7672 -17.7087
15 C1a C 20.3245 -12.1676
16 O5x O 22.5198 -13.3081
17 C8x C 17.3603 -17.7403
18 C8x C 16.6880 -18.9683
19 C8x C 17.4154 -20.1645
20 C8x C 18.8222 -20.1326
21 C8x C 19.4945 -18.9046
BOND 23
1 3 4 1
2 1 5 1
3 4 6 1
4 2 3 1
5 5 7 1
6 1 2 1
7 6 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 6 11 2
13 9 12 1
14 1 13 2
15 5 14 1
16 4 15 1
17 3 16 2
18 14 17 2
19 17 18 1
20 18 19 2
21 19 20 1
22 20 21 2
23 14 21 1
|
|---|
